A
Akero
1 follower
Akero Therapeutics is a clinical-stage cardio-metabolic company developing transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero's lead product candidate, efruxifermin (EFX), an engineered Fc-FGF21 fusion protein, is currently being eva... Read more
Org chart
Andrew Cheng
President & CEO
Collapse
Jonathan Young
COO & Co Founder
Tim Rolph
Chief Scientific Officer & Co-Founder
William White
CFO & Head of Corporate Development
Catriona Yale
Chief Development Officer
Dominick Villani
VP & Quality
Brittany de Temple
VP of Development Operations
Libette Luce
VP of Regulatory Affairs
Patrick Lamy
SVP, Commercial Strategy
Kitty Yale
EVP And Chief Development Officer
David West
Vice President Legal
Board & advisors
Mark Iwicki
Board Chair
Graham Walmsley
Director
Jane Pritchett Henderson
Director
Seth L. Harrison
Director
Tom Heyman
Director
Yuan Xu
Director
Teams
Offices
Similar companies
Cellares
2 followers
Tango Therapeutics
2 followers
Dyno Therapeutics
4 followers
Odyssey Therapeutics
2 followers
Gilead Sciences
144 followers
Regeneron
111 followers
Illumina
76 followers
Agilent Technologies
76 followers
Verily Life Sciences
41 followers
Alexion Pharmaceuticals
39 followers
GRAIL
27 followers
Explore companies